Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TANDEARIL is an oral small-molecule tablet approved in 1960 by Novartis with unknown mechanism of action and indication profile. The drug's specific therapeutic target and patient population cannot be determined from available data.
Product approaching loss of exclusivity signals declining team size and shift from growth to lifecycle management and generic transition support.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings indicate minimal active hiring; this product is in portfolio maintenance mode. Career growth is limited; opportunities exist primarily in defending market share and managing generic transition.
Worked on TANDEARIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.